bluebird bio sets up European commercial manufacturing capability

15 December 2016
2019_biotech_test_vial_discovery_big

US clinical-stage biotech firm bluebird bio (Nasdaq: BLUE) saw its shares rise 1.3% to $69.90 in early today, after it revealed forward looking plans to manufacture its products in Europe.

It announced a strategic manufacturing agreement with German company apceth Save Biopharma providing for the future European commercial production of bluebird bio’s Lenti-D product candidate for cerebral adrenoleukodystropy and its LentiGlobin product candidate for transfusion-dependent β-thalassemia.

This agreement follows a successful multi-year manufacturing relationship and provides bluebird bio with European commercial manufacturing capabilities, including dedicated production suites within apceth Biopharma’s state-of-the-art GMP facility.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology